TEVA-SPIRONOLACTONE/HCTZ 25 MG
HYDROCHLOROTHIAZIDE : 25 MG SPIRONOLACTONE : 25 MG · DIN 00613231 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-SPIRONOLACTONE/HCTZ?
TEVA-SPIRONOLACTONE/HCTZ 25 MG contains HYDROCHLOROTHIAZIDE : 25 MG SPIRONOLACTONE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 00613231, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Jun-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-SPIRONOLACTONE/HCTZ used for?
Edematous conditions (congestive heart failure, cirrhosis with ascites, nephrotic syndrome) and essential hypertension. Not for initial therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00613231 |
|---|---|
| Brand name | TEVA-SPIRONOLACTONE/HCTZ |
| Generic / active ingredient | HYDROCHLOROTHIAZIDE : 25 MG SPIRONOLACTONE : 25 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS |
| AHFS class | 24:32.20 ; 40:28.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Jun-2011 |
| Original market date | 1984-12-31 00:00:00 |
How is it administered?
Adult edema: 2-4 tablets (25/25mg) or 1-2 tablets (50/50mg) daily. Hypertension: 2-4 tablets (25/25mg) or 1-2 tablets (50/50mg) daily. Titrate individual components before using fixed-dose combination.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to section 11).
How is it supplied?
Bottles of 100 tablets.
Contraindications
Hypersensitivity to ingredients or sulfonamides; anuria; Addison’s disease; acute renal insufficiency; severe renal impairment (GFR < 30 mL/Min/1.73 m2); hyperkalemia; hypercalcemia; pregnancy; nursing.
Warnings and precautions
Avoid potassium supplements/high-potassium foods. Risk of hyperkalemia, gynecomastia, non-melanoma skin cancer, and acute angle-closure glaucoma. May cause somnolence/dizziness.
What can be used instead?
Other Canadian products sharing ATC code C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS. 5 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-AMILZIDE | 5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00784400 |
| APO TRIAZIDE | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 00441775 |
| TEVA-SPIRONOLACTONE/HCTZ | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00657182 |
| TEVA-TRIAMTERENE/HCTZ | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00532657 |
| ALDACTAZIDE 25 | 25 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00180408 |
| ALDACTAZIDE 50 | 50 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00594377 |
| ALTI-AMILORIDE HCTZ | 50 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 02174596 |
| AMI-HYDRO TAB | 50 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00870943 |
| APO-SPIROZIDE TAB | 25 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00520802 |
| DYAZIDE TAB | 50 MG | TABLET | SMITHKLINE BEECHAM PHARMA DIVISION OF SMITHKLINE BEECHAM INC | CANCELLED POST MARKET | DIN 01919547 |
Who else supplies HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS appears in 53 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.